A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042)
Abstract Dostarlimab is a humanized anti–PD-1 monoclonal antibody. Dostarlimab (JEMPERLI; TSR-042) was recently approved in the USA and in the EU. The presence of neutralizing antibodies (NAbs) is a cause for concern because they block the therapeutic function of the antibody and reduce drug efficac...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
SpringerOpen
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/9cc562b825a24dee8a7fce5d389aa00c |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|